Myocardial injury assessment in severe Covid-19 patients at the Intensive Care Unit in Sa Dec General Hospital

Hoang Trung Kien, Nguyen Tran Thuy, Bui Thi Thu Thuy, Bui Thi Lien, Nguyen Thi Tram, Nghiem Huyen Trang, Vu Phuong Nga, Nguyen Van Huynh, Tran Thanh Tung, Phan Thao Nguyen

Main Article Content

Abstract

Overview


Covid-19 is an emerging infectious disease, and a current pandemic with the death rate about 2.3%. It causes cardiovascular complications. Myocardial injury (MI) is the most common one.


Method


50 inpatients at Sa Dec General Hospital from 1st Aug to 10th Sep, 2021 were recruited, and divided into 2 groups (with and without MI, which based on levels of Troponin Ths on admission).


Results


Patient characteristics, clinical manifestations, and lab tests were assessed and compared between two groups. Comparison to the group without MI, the group with MI has higher age (68.33 ± 14.67 vs 55.65 ± 15.09, p = 0.004), more underlying cardiovascular diseases (34.1% vs 11.1%, p = 0.02), and coronary artery disease (19.6% vs 2.8%, p = 0.03). MI increases 28-day mortality rate in the intensive care unit (p = 0.002). The age of more than 60 also contributes to increase the mortality rate.


Conclusion


Myocardial injury is a common complication in severe Covid-19 patients, which increases the mortality rate in this group.

Article Details

References

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648
2. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. The American Journal of Emergency Medicine. 2020;38(7):1504. doi:10.1016/j.ajem.2020.04.048
3. Qian H, Gao P, Tian R, et al. Myocardial Injury on Admission as a Risk in Critically Ill COVID-19 Patients: A Retrospective in-ICU Study. Journal of Cardiothoracic and Vascular Anesthesia. 2021;35(3):846-853. doi:10.1053/j.jvca.2020.10.019
4. Ha K, A R, S L, K H, T S, W K. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. Journal of molecular and cellular cardiology. 1989;21(12). doi:10.1016/0022-2828(89)90680-9
5. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology. 2018;72(18):2231-2264. doi:10.1016/j.jacc.2018.08.1038
6. Lim W, Qushmaq I, Cook DJ, Crowther MA, Heels-Ansdell D, Devereaux P. Elevated troponin and myocardial infarction in the intensive care unit: a prospective study. Crit Care. 2005;9(6):R636-R644. doi:10.1186/cc3816
7. AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. JAMA Cardiology. 2020;5(7):747-748. doi:10.1001/jamacardio.2020.1329
8. Noble JS, Reid AM, Jordan LV, Glen AC, Davidson JA. Troponin I and myocardial injury in the ICU. Br J Anaesth. 1999;82(1):41-46. doi:10.1093/bja/82.1.41
9. Li L, Hill J, Spratt JC, Jin Z. Myocardial injury in severe COVID-19: Identification and management. Resuscitation. 2021;160:16-17. doi:10.1016/j.resuscitation.2020.11.040
10. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393